Effect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2

Life Sciences

Volumn 72, Issue 3, 2002, Pages 247-256

  Kaihara, Shinji ^a   Bessho, Kazuhisa ^a   Okubo, Yasunori ^a   Sonobe, Junya ^a   Kusumoto, Kenji ^b   Ogawa, Yutaka ^b   Iizuka, Tadahiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Collagen; FK506; Immunosuppression; Osteoinduction; Recombinant human BMP

Indexed keywords

ATELOCOLLAGEN; ATELOPEPTIDE TYPE I COLLAGEN; CELLMATRIX; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE GROWTH; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GASTROCNEMIUS MUSCLE; HISTOLOGY; IMPLANTATION; MALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; RADIOGRAPHY; RAT; RAT STRAIN;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CALCIUM; CARTILAGE; COLLAGEN; DRUG CARRIERS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MALE; MUSCLES; OSTEOGENESIS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

RATTUS NORVEGICUS;

EID: 0037032620     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02244-0     Document Type: Article

References (14)

1. Yoshikawa T., Nakajima H., Yamada E., Akahane M., Dohi Y., Ohgushi H., Tamai S., Ichijima K. In vivo osteogeneic capability of cultured allogeneic bone in porous hydroxvapatite: Immunosuppressive and osteogeneic potential of FK506 in vivo. Journal of Bone and Mineral Research. 15:2000;1147-1157.
2. Fujimura K., Bessho K., Kusumoto K., Yutaka O., Iizuka T. Experimental studies on bone inducing activity of composites of atelopeptide type I collagen as a carrier for ectopic osteoinduction by rhBMP-2. Biochemical Biophysical Research Communications. 208:1995;316-322.
3. Okubo Y., Bessho K., Fujimura K., Kusumoto K., Yutaka O., Yoshiaki T., Iizuka T. Comparative study of intramuscular and intraskeletal osteogenesis by recombinant human bone morphogenetic protein-2. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics. 87:1999;34-38.
4. Okubo Y., Bessho K., Fujimura K., Konishi Y., Kusumoto K., Yutaka O., Yoshiaki T., Iizuka T. Osteoriduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermusucular, subcutaneous and intrafatty sites. International Journal Oral and Maxillofacial Surgery. 29:2000;62-66.
5. Voggenretter G., Assenmacher S., Kreuzfelder E., Wolf M., Kim M., Nast-Kolb D., Schade F.U. Immunosuppression with FK506 increases bone induction in demineralized isogeneic and xenogeneic bone matrix in the rat. Journal of Bone and Mineral Research. 15:2000;1825-1834.
6. Cvetkovic M., Mann G.N., Romero D.F., Liango X.G., Ma Y., Jee W.S., Epstein S. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation. 57:1994;1231-1237.
7. Ruppert R., Hoffmann E., Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. European Journal of Biochemistry. 237:1996;295-302.
8. Akahane M., Ohgushi H., Yoshikawa T., Sempuku T., Tamai S., Tabata S., Dohi Y. Osteogeneic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. Journal of Bone and Mineral Research. 14:1999;561-568.
9. Connetry H.V., Briggs A.R. Determination of serum calcium by means of orthocresolphthalein complexone. American Journal of Clinical Pathology. 45:1966;290-296.
10. The executive board in analytical section, the committee of enzymes in analytical section of Japan Society of Clinical Chemistry. Provisional recommendation for measurement of catalytic concentration of alkaline phosphatase in serum. The Executive Board in Analytical Section, the Committee of Enzymes in Analytical Section of Japan Society of Clinical Chemistry 1988;1:11-9.
11. Liu J., Farmer J.D. Jr., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
12. O'Keefe S.J., Tamura J., Kincaid R.L., Tocci M.J., O'Neill E.A. FK506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature. 357:1992;692-694.
13. Valentin-Opran A., Wozney J., Csimma C., Lilly L., Riedel G.E. Clinical evaluation of recombinant human bone morphogenetic protein-2. Clinical Orthopaedics and Related Research. 395:2002;110-120.
14. Kokado Y., Takahara S. Hypertension depends on immunosuppressant. Ketsuatu. 6:1999;923-936. [Japanese].